A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Completed · Phase 1

Conditions studied: Hepatic Insufficiency

In brief

This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function. This study will also evaluate the safety and tolerability of CP-690,550.

Key facts

Study ID

NCT00969813

Run by

Pfizer

People needed

18

Starts

2009-11-01

Expected to finish

2010-01-01

Last updated by the study team

2010-02-11

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers who have normal liver function, and subjects who have either mild or moderate liver impairment.

You may not qualify if…

• Subjects with severe liver impairment
• Subjects who have weakened immune systems

Where it is running

• Pfizer Investigational Site — South Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.